$522 Million is the total value of Ally Bridge Group (NY) LLC's 32 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 46.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Sell | SPDR SER TRput | $108,520,000 | -29.9% | 800,000 | -27.3% | 20.80% | -21.6% | |
| AVIR | Sell | ATEA PHARMACEUTICALS INC | $55,803,000 | +31.4% | 903,688 | -11.1% | 10.70% | +47.0% |
| MDVL | MEDAVAIL HOLDINGS INC | $40,891,000 | -7.0% | 2,920,780 | 0.0% | 7.84% | +4.1% | |
| CERE | Sell | CEREVEL THERAPEUTICS HLDNG I | $23,734,000 | -19.0% | 1,728,590 | -2.2% | 4.55% | -9.4% |
| SYRS | Buy | SYROS PHARMACEUTICALS INC | $23,486,000 | -18.1% | 3,139,895 | +18.8% | 4.50% | -8.3% |
| FATE | Buy | FATE THERAPEUTICS INC | $22,262,000 | -5.8% | 270,000 | +3.8% | 4.27% | +5.3% |
| NTRA | Buy | NATERA INC | $22,136,000 | +18.3% | 218,000 | +16.0% | 4.24% | +32.4% |
| NUVB | New | NUVATION BIO INC | $20,900,000 | – | 2,000,000 | +100.0% | 4.01% | – |
| NTLA | INTELLIA THERAPEUTICS INC | $18,057,000 | +47.5% | 225,000 | 0.0% | 3.46% | +65.0% | |
| RGEN | REPLIGEN CORP | $16,039,000 | +1.5% | 82,500 | 0.0% | 3.08% | +13.5% | |
| COGT | UNUM THERAPEUTICS INC | $14,246,000 | -21.8% | 1,622,591 | 0.0% | 2.73% | -12.6% | |
| IOVA | Buy | IOVANCE BIOTHERAPEUTICS INC | $12,885,000 | -22.9% | 406,986 | +13.1% | 2.47% | -13.7% |
| VRDN | New | VIRIDIAN THERAPEUTICS INC | $11,376,000 | – | 680,768 | +100.0% | 2.18% | – |
| ITOS | ITEOS THERAPEUTICS INC | $11,033,000 | +1.1% | 322,794 | 0.0% | 2.12% | +13.0% | |
| EPIX | Buy | ESSA PHARMA INC | $10,551,000 | +1030.9% | 363,185 | +364.5% | 2.02% | +1164.4% |
| ORIC | ORIC PHARMACEUTICALS INC | $10,120,000 | -27.6% | 413,061 | 0.0% | 1.94% | -19.0% | |
| CVAC | New | CUREVAC N V | $10,061,000 | – | 110,000 | +100.0% | 1.93% | – |
| APLS | APELLIS PHARMACEUTICALS INC | $9,869,000 | -25.0% | 230,000 | 0.0% | 1.89% | -16.1% | |
| BOLT | New | BOLT BIOTHERAPEUTICS INC | $9,469,000 | – | 287,725 | +100.0% | 1.82% | – |
| APTOSE BIOSCIENCES INC | $8,420,000 | +36.4% | 1,409,150 | 0.0% | 1.61% | +52.6% | ||
| OLK | New | OLINK HLDG ABsponsored ads | $7,200,000 | – | 200,000 | +100.0% | 1.38% | – |
| ARVN | Buy | ARVINAS INC | $6,891,000 | -18.9% | 104,253 | +4.3% | 1.32% | -9.2% |
| CSTL | Sell | CASTLE BIOSCIENCES INC | $6,846,000 | -51.5% | 100,000 | -52.4% | 1.31% | -45.7% |
| ITMR | Sell | ITAMAR MED LTDsponsored ads | $6,552,000 | -34.3% | 273,569 | -45.5% | 1.26% | -26.5% |
| FDMT | 4D MOLECULAR THERAPEUTICS IN | $6,507,000 | +4.6% | 150,000 | 0.0% | 1.25% | +17.1% | |
| SBTX | SILVERBACK THERAPEUTICS INC | $5,610,000 | -5.8% | 128,572 | 0.0% | 1.08% | +5.4% | |
| ACET | New | ADICET BIO INC | $5,559,000 | – | 425,000 | +100.0% | 1.07% | – |
| FRLN | Sell | FREELINE THERAPEUTICS HLDGSsponsored ads | $5,027,000 | -35.2% | 408,726 | -3.8% | 0.96% | -27.5% |
| IMVT | New | IMMUNOVANT INC | $4,170,000 | – | 260,000 | +100.0% | 0.80% | – |
| ORTX | ORCHARD THERAPEUTICS PLCads | $3,974,000 | +68.0% | 547,427 | 0.0% | 0.76% | +88.1% | |
| LUNG | Sell | PULMONX CORP | $2,696,000 | -80.4% | 58,939 | -70.4% | 0.52% | -78.0% |
| IDYA | New | IDEAYA BIOSCIENCES INC | $705,000 | – | 30,000 | +100.0% | 0.14% | – |
| NSTG | Exit | NANOSTRING TECHNOLOGIES INC | $0 | – | -9,277 | -100.0% | -0.11% | – |
| ONCT | Exit | ONCTERNAL THERAPEUTICS INC | $0 | – | -300,000 | -100.0% | -0.25% | – |
| KDNY | Exit | CHINOOK THERAPEUTICS INC | $0 | – | -199,600 | -100.0% | -0.54% | – |
| VIR | Exit | VIR BIOTECHNOLOGY INC | $0 | – | -275,000 | -100.0% | -1.26% | – |
| AUPH | Exit | AURINIA PHARMACEUTICALS INC | $0 | – | -858,032 | -100.0% | -2.03% | – |
| Exit | SAREPTA THERAPEUTICS INCcall | $0 | – | -238,600 | -100.0% | -6.97% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Fan Yu #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-17
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MEDAVAIL HOLDINGS INC | 11 | Q2 2023 | 8.9% |
| UNUM THERAPEUTICS INC | 8 | Q3 2022 | 7.3% |
| RAPID MICRO BIOSYSTEMS INC-A | 8 | Q2 2023 | 3.5% |
| FATE THERAPEUTICS INC | 7 | Q2 2022 | 5.8% |
| VIRIDIAN THERAPEUTICS INC | 7 | Q2 2023 | 6.8% |
| SYROS PHARMACEUTICALS INC | 7 | Q2 2022 | 4.9% |
| REPLIGEN CORP | 7 | Q4 2022 | 6.5% |
| NAUTILUS BIOTECHNOLOGY INC | 7 | Q4 2022 | 3.8% |
| ARVINAS INC | 6 | Q1 2022 | 7.5% |
| NUVATION BIO INC | 6 | Q2 2022 | 4.9% |
View Ally Bridge Group (NY) LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cogent Biosciences, Inc. | November 19, 2020 | 1,420,500 | 8.0% |
View Ally Bridge Group (NY) LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 4 | 2023-06-21 |
| 13F-HR | 2023-05-15 |
| 4 | 2023-03-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
View Ally Bridge Group (NY) LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.